StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN)

Investment analysts at StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a report issued on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $5.00 target price on shares of Trevena in a research report on Thursday, November 14th.

Trevena Stock Down 1.4 %

NASDAQ:TRVN opened at $1.76 on Friday. The stock has a market cap of $1.52 million, a P/E ratio of -0.04 and a beta of 1.08. The business’s 50-day moving average price is $1.80 and its two-hundred day moving average price is $4.07. Trevena has a twelve month low of $1.13 and a twelve month high of $19.23.

Trevena (NASDAQ:TRVN) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The company had revenue of $0.28 million for the quarter. On average, equities research analysts expect that Trevena will post -23.04 EPS for the current fiscal year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.